#BreakingNews: Data from the first computational biomarker analysis of TROP2 in the TROPION-Lung01 phase 3 trial was featured during Presidential Symposium 1 at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. Click the image to learn more and follow us throughout the conference for #WCLC24 news.
Daiichi Sankyo US
Pharmaceutical Manufacturing
Basking Ridge, NJ 190,995 followers
We create life-changing solutions for patients.
About us
At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8
- Website
-
https://daiichisankyo.us/
External link for Daiichi Sankyo US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basking Ridge, NJ
- Type
- Public Company
- Specialties
- Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo group of companies and is focused on the development of oncology therapies and specialty medicines., Oncology, and Specialty Medicine
Locations
-
Primary
211 Mt. Airy Road Basking Ridge
Basking Ridge, NJ 07920, US
Employees at Daiichi Sankyo US
-
Jak (J. C.) DeTemple
Top Talent Executive Recruiter to the Biotech/Pharma Industry Leadership Superstars! Top Talent Sourcing Guru! Talent Acquisition & Retention…
-
Hayes Williams
Global Head of Data Governance at Daiichi Sankyo, Inc.
-
Desmon Swanston
-
Joseph Prikazsky
Pharma/Biotech Financial Professional
Updates
-
#BreakingNews: Today during an oral presentation at #WCLC24, in collaboration with Merck, results from the ongoing IDeate-Lung01 phase 2 trial in patients with pretreated extensive-stage small cell lung cancer were presented. Click the image to learn more about these results and follow us for the latest #WCLC24 news.
Press Releases - Daiichi Sankyo US
daiichisankyo.us
-
Interested in a PharmD Fellowship at Daiichi Sankyo US? Our 2025 - 2027 recruitment cycle is now open! (👀⬇ link for details) 👋 Meet with members of the Daiichi Sankyo US team at Rutgers Pharmaceutical Industry Fellowship (RPIF) Program Fellowship Information and Networking Day (FIND) to learn more about us, our open positions and how your unique skills and contributions can help in creating better tomorrows for patients. 🔗 2025 Daiichi Sankyo RPIF Brochure: https://bit.ly/3TfXWFu 📍 FIND us on September 11: https://bit.ly/3P8GC2w 📅 Networking sessions run from September 16–26 #PharmD #Fellowship #Hiring
-
⏱Every two seconds someone in the U.S. needs blood—for surgery, cancer treatment, chronic illnesses and traumatic injuries. Driven by our collective purpose and the knowledge that one 🩸 donation can help save more than one life, our BELIEVE BERG (Black Employees Leading in Inclusion, Excellence, Vision & Empowerment) hosted its second blood drive of the year for employees at our US office. 🙋♀️ Want to get involved this National Blood Donation Week? Check out https://lnkd.in/djVuV_X #DSProud #BloodDonation
-
News Update: Throughout the International Association for the Study of Lung Cancer and ESMO - European Society for Medical Oncology 2024 congresses Daiichi Sankyo US will present: ✔ 25 abstracts across multiple types of cancer ✔ Six late-breaking presentations across lung and breast cancer trials of our DXd ADCs ✔ Two Presidential Symposia at #WCLC24 ✔ The first ever clinical data from our second ADC platform at #ESMO24 Follow us throughout #ESMO24 & #WCLC24 for the latest oncology news from Daiichi Sankyo. Click the image to learn more about the new research across our industry-leading ADC portfolio throughout both congresses. https://bit.ly/4cTkinh
Press Releases - Daiichi Sankyo US
daiichisankyo.us
-
What's your go to for building trust and connection? 'Collaborate & Trust' is one of our core behaviors at Daiichi Sankyo US, and the foundation by which our teams are able to innovate and thrive together. For Michael Lebiszczak, one of our Coaches of the Year, "when challenging situations arise, I focus in on finding a solution that builds both connection and trust with my team. That common ground and focus often helps instill confidence in the team and our path forward." #DSProud
-
Every person has the power to make their goals a reality—at home and at work. Today is a reminder that you’re not alone in that journey. Our Women's Forum Business Employee Resource Group (BERG) recently celebrated Women’s Equality Day with a powerful session on fostering an inclusive and supportive environment that champions women at all levels. 🔽 We do this through: ✨ Mentorship: Formally within Daiichi Sankyo and through partnerships with external professional organizations like Healthcare Businesswomen’s Association, Women of Color in Pharma (WOCIP) and Latinos in Bio ✨ Professional development: Providing resources and opportunities for skill enhancement, leadership training, and personal growth ✨ Allyship: Encouraging all employees in advocating for gender equality, both within our organization and in the broader community. We strive to empower every woman in our workforce and contribute to a world where equality is not just a goal but a reality. 💬 How are you making your goals a reality? #WomensEqualityDay #Empowerment #DSProud
-
As Daiichi Sankyo US Global Team Lead, Oncology R&D, Dalila Sellami has seen firsthand the impact a new medicine can have on a patient and their family. Motivated, committed and passionate—she’s got that true “craftsperson’s spirit.” Watch the new episode “Where Craft Meets – Medicine” only on YouTube: https://bit.ly/471VU1G #WhereCraftMeets #oncology #cancer #innovation
-
Great read on our first Chief Compliance Officer, Matt Allegrucci and how he plans to use his 20 years of DS experience to develop a global compliance program and infrastructure.
We’re pleased to introduce our new Chief Compliance Officer Matt Allegrucci. A proven leader of more than 20 years at Daiichi Sankyo, Matt has been tasked with developing the company’s first global compliance program and infrastructure. The program will focus on maintaining trust at the center of Daiichi Sankyo’s growth and transformation. “The trust of patients, physicians and everyone with a stake in our business is essential to the long-term success of the organization and our mission. The job of compliance, simply put, is to ensure we earn that trust.” Click to read how the importance of trust was instilled in Matt at a young age and became a central tenet of his career—and how he and his team help make compliance training fun. Passion for Innovation. Compassion for Patients.®
Keeping Integrity and Trust at the Center of Global Transformation - Chief Compliance Officer, Matt Allegrucci
daiichisankyo.com
-
#BREAKINGNEWS: The FDA has granted Breakthrough Therapy Designation for our #ADC for certain previously treated patients with metastatic #BreastCancer. This is the 11th designation across the Daiichi Sankyo oncology pipeline. Click the image for more information on the filing and what it may mean for patients impacted by these cancers.
Press Releases - Daiichi Sankyo US
daiichisankyo.us